conjugates adcs class biopharmaceutical drugs designed targeted therapy treating unlike chemotherapy adcs intended target kill tumor cells sparing healthy cells pharmaceutical companies developing adcs complex molecules composed antibody linked biologically active cytotoxic anticancer payload conjugates example bioconjugates immunoconjugates adcs combine targeting properties monoclonal antibodies cancerkilling capabilities cytotoxic drugs designed discriminate healthy diseased anticancer drug coupled antibody targets specific tumor antigen protein ideally found tumor cells antibodies attach antigens surface cancerous cells biochemical reaction occurs upon attaching triggers signal tumor cell absorbs internalizes antibody together linked cytotoxin adc internalized cytotoxin kills targeting ability believed limit side effects cancer patients give wider therapeutic window chemotherapeutic agents although promise hasnt yet realized clinic adc technologies featured many including scientific journals idea drugs would target tumor cells ignore others conceived german nobel laureate paul ehrlich described drugs magic bullet due targeting pfizerwyeths drug gemtuzumab ozogamicin trade name mylotarg approved based study surrogate endpoint accelerated approval process june evidence accumulated showing evidence benefit significant toxicity us food drug administration fda forced company withdraw reintroduced us market brentuximab vedotin trade name adcetris marketed seattle genetics approved relapsed hl relapsed systemic anaplastic largecell lymphoma salcl fda august received conditional marketing authorization european medicines agency october trastuzumab emtansine adotrastuzumab emtansine trade name kadcyla marketed genentech roche approved february treatment people metastatic breast cancer mbc received prior treatment trastuzumab taxane european commission approved inotuzumab monotherapy treatment adults relapsed refractory bcell precursor acute lymphoblastic leukemia june trade name followed august first immunology conjugate iadc showed improvement disease activity phase study patients rheumatoid study second iadc evaluate adverse events change disease activity participants treated subcutaneous injection july daiichi sankyo company limited glycotope gmbh inked pact regarding combination glycotopes investigational tumorassociated antibody gatipotuzumab daiichi sankyos proprietary adc technology developing gatipotuzumab antibody drug astrazeneca agreed pay billion jointly develop japans daiichi sankyo intended replace herceptin treating breast cancer carries eight payloads compared usual thirteen adcs received market approval fda oncotherapies belantamab mafodotin process withdrawn us marketing conjugate consists antibody targets cancer cell surface may also elicit therapeutic response payload elicits desired therapeutic response linker attaches payload antibody stable circulation releasing payload desired target multiple approaches conjugation developed attachment antibody dar drug antibody ratio indicates level loading payload adc many payloads oncology adcs oadc natural product based making covalent interactions payloads include microtubulin inhibitors monomethyl auristatin monomethyl auristatin f dna binder topoisomerase inhibitors resulting renaissance natural product total glucocorticoid receptor modulators grm represent active payload class iadcsclarification needed approaches releasing marketed grm molecules like developed modified grm also developed enable attachment linker term adcidified describing medicinal chemistry process payload optimization facilitate linker alternatives small molecule payloads also investigated example stable link antibody cytotoxic anticancer agent crucial aspect stable adc linker ensures less cytotoxic payload falls reaching tumor cell improving safety limiting dosages linkers based chemical motifs including disulfides hydrazones peptides cleavable thioethers noncleavable cleavable noncleavable linkers proved safe preclinical clinical trials brentuximab vedotin includes enzymesensitive cleavable linker delivers antimicrotubule agent monomethyl auristatin e mmae synthetic antineoplastic agent humanspecific malignant cells mmae inhibits cell division blocking polymerization tubulin high toxicity mmae used singleagent chemotherapeutic drug however mmae linked monoclonal antibody cell membrane protein tumor necrosis factor tnf receptor stable extracellular fluid cleavable cathepsin safe therapy trastuzumab emtansine combination microtubuleformation inhibitor mertansine antibody trastuzumab employs stable noncleavable linker availability better stable linkers changed function chemical bond type linker cleavable noncleavable lends specific properties cytotoxic drug example noncleavable linker keeps drug within cell result entire antibody linker cytotoxic anticancer agent enter targeted cancer cell antibody degraded amino acid resulting complex amino acid linker cytotoxic agent considered active drug contrast cleavable linkers detached enzymes cancer cell cytotoxic payload escape targeted cell process called bystander killing attack neighboring another type cleavable linker currently development adds extra molecule cytotoxin cleavage site allows researchers create adcs flexibility without changing cleavage kinetics researchers developing new method peptide cleavage based edman degradation method sequencing amino acids also development sitespecific conjugation novel conjugation improve stability therapeutic index Î± emitting antibodyconjugated antibodyoligonucleotide conjugate field matured accurate definition adc anythingdrug conjugate alternatives antibody targeting component include multiple smaller antibody like bicyclic first generation uses linking technologies conjugate drugs nonselectively cysteine lysine residues antibody resulting heterogeneous mixture approach leads suboptimal safety efficacy complicates optimization biological physical pharmacological sitespecific incorporation unnatural amino acids generates site controlled stable attachment enables production homogeneous adcs antibody precisely linked drug controlled ratios antibody drug allowing selection bestinclass escherichia colibased open cellfree synthesis ocfs allows synthesis proteins containing sitespecifically incorporated nonnatural amino acids optimized predictable highyield protein synthesis folding absence cell wall allows addition nonnatural factors system manipulate transcription translation folding provide precise protein expression majority adcs development clinical trials oncological hematological primarily driven inventory monoclonal antibodies target various types cancer however developers looking expand application important disease